Laza-Briviesca, RaquelCruz-Bermúdez, AlbertoNadal, ErnestInsa, AmeliaGarcía-Campelo, María Del RosarioHuidobro, GerardoDómine, ManuelMajem, MargaritaRodríguez-Abreu, DelvysMartínez-Martí, AlexDe Castro Carpeño, JavierCobo, ManuelLópez Vivanco, GuillermoDel Barco, EdelBernabé Caro, ReyesViñolas, NuriaBarneto Aranda, IsidoroViteri, SantiagoMassuti, BartomeuCasarrubios, MartaSierra-Rodero, BelénTarín, CarlosGarcía-Grande, AránzazuHaymaker, CaraWistuba, Ignacio IRomero, AtochaFranco, FernandoProvencio, Mariano2025-01-072025-01-072021https://hdl.handle.net/10668/25724Immunotherapy is being tested in early-stage non-small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care. Early identification of CPR patients has vital clinical implications. In this study, we focused on basal peripheral immune cells and their treatment-related changes to find biomarkers associated to CPR. Blood from 29 stage IIIA NSCLC patients participating in the NADIM trial (NCT03081689) was collected at diagnosis and post neoadjuvant treatment. More than 400 parameters of peripheral blood mononuclear cells (PBMCs) phenotype and plasma soluble factors were analyzed. Neoadjuvant chemoimmunotherapy altered more than 150 immune parameters. At diagnosis, 11 biomarkers associated to CPR were described, with an area under the ROC curve >0.70 and p-value 0.70 and p-value Patients achieving CPR seem to have a distinctive peripheral blood immune status at diagnosis, even showing different immune response to treatment. These results reinforce the different biology behind CPR and non-CPR responses.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/biomarkerschemoimmunotherapyimmune cellsneoadjuvantnon-small cell lung cancerAgedAntigens, CD19Antineoplastic AgentsArea Under CurveB-Cell Maturation AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleHumansImmunotherapyLeukocytes, MononuclearLung NeoplasmsMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingNerve Growth FactorNeurotrophin 3ROC CurveVascular Endothelial Growth Factor Dresearch article34323406open access10.1002/ctm2.4912001-1326PMC8288017https://idus.us.es/bitstream/11441/140183/1/Blood%20biomarkers%20associated%20to%20complete%20pathological%20response%20on%20NSCLC%20patients%20treated%20with%20neoadjuvant%20chemoimmunotherapy%20included%20in%20NADIM%20clinical%20trial.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8288017/pdf